Response to Comments: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

This policy document (A59131) is a response to public comments and does not define coverage criteria itself. It directs readers to MolDX LCD L38974, which was retitled to focus on lab-developed tests for inherited cancer syndromes in patients with cancer and became effective 2022-08-08; consult that LCD for specific indications, limitations, documentation, and frequency rules.

"This document is a response to comments on LCD L38974 and does not itself specify coverage criteria; refer to MolDX LCD L38974 (effective 2022-08-08) for the lab-developed test coverage policy for ..."

Sign up to see full coverage criteria, indications, and limitations.